In line with EMBO's reputation for promoting the very best in the molecular life sciences, a renowned group of senior editors and an equally well respected advisory board assure published articles of the highest scientific quality following rapid, transparent and rigorous peer review.
"EMBO Molecular Medicine offers a unique opportunity to broadly distribute new findings in biomedical research and to strengthen links between clinicians and molecular biologists," said Hermann Bujard, EMBO Director. "We hope that published papers will lead to advances that will improve the detection, diagnosis and clinical management of diseases."
Articles will appear online and in print. In addition to research articles, the journal will publish review articles and editorials with innovative formats targeting a broad and unspecialised audience. A new format of review article, called Bridging the Gap, will aim to help molecular biologists and clinical researchers to understand each other's perspectives and to define common goals.
Submissions are invited from research groups at universities, independent research laboratories and pharmaceutical and biotechnology companies worldwide. EMBO Molecular Medicine offers free access to all content for the first two years of publication.
EMBO Molecular Medicine is published for EMBO by Wiley-Blackwell (the scientific, technical, medical, and scholarly publishing business of John Wiley & Sons, Inc.) and joins the EMBO family of leading peer-reviewed journals - The EMBO Journal, EMBO reports and Molecular Systems Biology - that span a broad spectrum of topics of molecular biology and reflect how science is shaping the world.